SUBSCRIBE
SUBSCRIBE
News   Drug Development

Sanofi-Aventis (France) Prostate Cancer Drug, Cabazitaxel Shows 28% Survival

May 27, 2010 | 
1 min read
Reuters -- Sanofi-Aventis' (SASY.PA) cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.
Clinical research Phase III
Sanofi (France)
MORE ON THIS TOPIC
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
stairs going upward
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
January 12, 2026
 · 
6 min read
 · 
Heather McKenzie